Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alector, Inc.ALEC · Entity 6051 | Director | June 17, 2026 | June 17, 2026 |
| GYRE THERAPEUTICS, INC.CBIO · Entity 5247 | Director | October 01, 2021 | October 05, 2021 |
| Korsana Biosciences, Inc.CYCN · Entity 7698 | Director | November 30, 2023 | December 04, 2023 |
| Royalty Pharma plcRPRX · Entity 3100 | Director | May 13, 2025 | May 14, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alector, Inc.
Report date June 17, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 98,650 |
Reported balance
After 2026-06-17 transaction · row 1
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 28,700 · Balance 98,650 F1: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 16, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2036-06-16 | Direct | 9,450 |
Reported balance
After 2026-06-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-17 · Grant · Acquired 9,450 · Balance 9,450 F2: The shares subject to the option vest in 12 equal monthly installments beginning on July 17, 2026, provided that the shares subject to the option will vest in full on the earlier of the one-year anniversary of the date of grant or the date of the Issuer's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 16, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders.
F2: The shares subject to the option vest in 12 equal monthly installments beginning on July 17, 2026, provided that the shares subject to the option will vest in full on the earlier of the one-year anniversary of the date of grant or the date of the Issuer's next annual meeting of stockholders.
GYRE THERAPEUTICS, INC.
Report date October 01, 2021 · Filed October 05, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 29,801 |
Reported balance
After 2021-10-01 transaction · row 1
1 source rowRow 1 · 2021-10-01 · Grant · Acquired 3,588 · Balance 29,801 F1: Represents shares of common stock received in lieu of fees. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock received in lieu of fees.
Korsana Biosciences, Inc.
Report date November 30, 2023 · Filed December 04, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 50,000 |
Reported balance
After 2023-11-30 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2023-11-30 · Grant · Acquired 20,000 · Balance 50,000 F1: The Reporting Person was granted 20,000 shares of restricted stock pursuant to the Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan. 2,500 of these shares vest immediately and the remaining 17,500 shares vest ratably over a 42-month period, provided that the Reporting Person remains as a director of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. |
| Common StockSEC Table I · non-derivative | Direct | 30,000 |
Reported balance
After 2023-11-30 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2023-11-30 · Grant · Acquired 30,000 · Balance 30,000 F2: The Reporting Person was granted 30,000 shares of restricted stock pursuant to the Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan. 3,750 of these shares vest immediately and the remaining 26,250 shares vest ratably over a 42-month period, provided that the Reporting Person remains as Chair of the Board of Directors of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted 20,000 shares of restricted stock pursuant to the Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan. 2,500 of these shares vest immediately and the remaining 17,500 shares vest ratably over a 42-month period, provided that the Reporting Person remains as a director of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions.
F2: The Reporting Person was granted 30,000 shares of restricted stock pursuant to the Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan. 3,750 of these shares vest immediately and the remaining 26,250 shares vest ratably over a 42-month period, provided that the Reporting Person remains as Chair of the Board of Directors of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions.
Royalty Pharma plc
Report date May 13, 2025 · Filed May 14, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary SharesSEC Table I · non-derivative | Direct | 81,352 |
Reported balance
After 2025-05-13 transaction · row 1
1 source rowRow 1 · 2025-05-13 · Grant · Acquired 7,614 · Balance 81,352 F1: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 17, 2026 20:05 UTC | Alector, Inc. ALEC · Entity 6051 | GrantStock Option (right to buy) · Derivative | 9,450 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-274123 · ownership.xml · derivative · entry 2 DESOUZA ERROL B · CIK 0001213895 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,450 Underlying: Common Stock · 9,450 shares Expires 2036-06-16 F2 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on July 17, 2026, provided that the shares subject to the option will vest in full on the earlier of the one-year anniversary of the date of grant or the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 17, 2026 Filed Jun 17, 2026 20:05 UTC | Alector, Inc. ALEC · Entity 6051 | GrantCommon Stock | 28,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-274123 · ownership.xml · nonDerivative · entry 1 DESOUZA ERROL B · CIK 0001213895 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,650 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 16, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 11, 2025 Filed Jun 12, 2025 22:05 UTC | Alector, Inc. ALEC · Entity 6051 | GrantStock Option (right to buy) · Derivative | 9,450 | $0.00 Strike: $1.63 | $0.00 |
DisclosureSEC source: 0000950170-25-085615 · ownership.xml · derivative · entry 2 DESOUZA ERROL B · CIK 0001213895 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,450 Underlying: Common Stock · 9,450 shares Expires 2035-06-10 F2 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on July 11, 2025, provided that the shares subject to the option will vest in full on the earlier of the one-year anniversary of the date of grant or the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 11, 2025 Filed Jun 12, 2025 22:05 UTC | Alector, Inc. ALEC · Entity 6051 | GrantCommon Stock | 28,700 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-085615 · ownership.xml · nonDerivative · entry 1 DESOUZA ERROL B · CIK 0001213895 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,950 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 11, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| May 13, 2025 Filed May 14, 2025 21:07 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 7,614 | $0.00 | $0.00 |
DisclosureSEC source: 0001802768-25-000049 · wk-form4_1747256848.xml · nonDerivative · entry 1 DESOUZA ERROL B · CIK 0001213895 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,352 F1 · shares: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. Read SEC document |
| June 07, 2024 Filed Jun 10, 2024 20:11 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 9,293 | $0.00 | $0.00 |
DisclosureSEC source: 0001802768-24-000027 · wk-form4_1718050260.xml · nonDerivative · entry 1 DESOUZA ERROL B · CIK 0001213895 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,738 F1 · shares: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. Read SEC document |
| March 19, 2024 Filed Mar 21, 2024 21:01 UTC | Alector, Inc. ALEC · Entity 6051 | GrantStock Option (right to buy) · Derivative | 19,420 | $0.00 Strike: $6.20 | $0.00 |
DisclosureSEC source: 0000950170-24-034848 · ownership.xml · derivative · entry 2 DESOUZA ERROL B · CIK 0001213895 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,420 Underlying: Common Stock · 19,420 shares Expires 2034-03-19 F2 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on April 19, 2024. Read SEC document |
| March 19, 2024 Filed Mar 21, 2024 21:01 UTC | Alector, Inc. ALEC · Entity 6051 | GrantCommon Stock | 41,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-034848 · ownership.xml · nonDerivative · entry 1 DESOUZA ERROL B · CIK 0001213895 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,250 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest in 12 equal quarterly installments beginning on September 1, 2024. Read SEC document |
| November 30, 2023 Filed Dec 4, 2023 21:05 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-067736 · ownership.xml · nonDerivative · entry 2 DESOUZA ERROL B · CIK 0001213895 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 F2 · shares: The Reporting Person was granted 30,000 shares of restricted stock pursuant to the Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan. 3,750 of these shares vest immediately and the remaining 26,250 shares vest ratably over a 42-month period, provided that the Reporting Person remains as Chair of the Board of Directors of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. Read SEC document |
| November 30, 2023 Filed Dec 4, 2023 21:05 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-067736 · ownership.xml · nonDerivative · entry 1 DESOUZA ERROL B · CIK 0001213895 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 F1 · shares: The Reporting Person was granted 20,000 shares of restricted stock pursuant to the Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan. 2,500 of these shares vest immediately and the remaining 17,500 shares vest ratably over a 42-month period, provided that the Reporting Person remains as a director of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. Read SEC document |
| June 23, 2023 Filed Jun 26, 2023 20:04 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 7,747 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-039672 · doc4.xml · nonDerivative · entry 1 DESOUZA ERROL B · CIK 0001213895 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,445 F1 · shares: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. Read SEC document |
| June 24, 2022 Filed Jun 24, 2022 20:55 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 6,328 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-024038 · doc4.xml · nonDerivative · entry 1 DESOUZA ERROL B · CIK 0001213895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,698 F1 · shares: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. Read SEC document |
| June 14, 2022 Filed Jun 17, 2022 00:55 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $0.53 | $0.00 |
DisclosureSEC source: 0001140361-22-023329 · form4.xml · derivative · entry 1 DESOUZA ERROL B · CIK 0001213895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-14 F1 · derivative.exercise_date: The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 20:32 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 3,588 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-059424 · doc4.xml · nonDerivative · entry 1 DESOUZA ERROL B · CIK 0001213895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,801 F1 · shares: Represents shares of common stock received in lieu of fees. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 13:51 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 3,406 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-044688 · doc4.xml · nonDerivative · entry 1 DESOUZA ERROL B · CIK 0001213895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,213 F1 · shares: Represents shares of common stock received in lieu of fees. Read SEC document |
| June 25, 2021 Filed Jun 30, 2021 00:34 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 5,726 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-21-009693 · dp153554_4-desouza.xml · nonDerivative · entry 1 DESOUZA ERROL B · CIK 0001213895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,370 F1 · shares: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 21:08 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $3.97 | $0.00 |
DisclosureSEC source: 0001140361-21-022547 · form4.xml · derivative · entry 1 DESOUZA ERROL B · CIK 0001213895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-24 F1 · derivative.exercise_date: The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date. Read SEC document |
| June 09, 2021 Filed Jul 2, 2021 13:51 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001209191-21-044688 · doc4.xml · derivative · entry 2 DESOUZA ERROL B · CIK 0001213895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2031-06-09 F2 · derivative.exercise_date: 100% of the shares subject to the option will vest and become exercisable on June 9, 2022, the one-year anniversary of the grant date. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 17:37 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 2,926 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-025028 · doc4.xml · nonDerivative · entry 1 DESOUZA ERROL B · CIK 0001213895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,807 F1 · shares: Represents shares of common stock received in lieu of fees. Read SEC document |
| January 05, 2021 Filed Jan 6, 2021 21:47 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 2,129 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002150 · doc4.xml · nonDerivative · entry 1 DESOUZA ERROL B · CIK 0001213895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,881 F1 · shares: Represents shares of common stock received in lieu of fees. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 20:17 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 3,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-053117 · doc4.xml · nonDerivative · entry 1 DESOUZA ERROL B · CIK 0001213895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,752 F1 · shares: Represents shares of common stock received in lieu of fees. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 20:41 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 2,129 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-040377 · doc4.xml · nonDerivative · entry 1 DESOUZA ERROL B · CIK 0001213895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,627 F1 · shares: Represents shares of common stock received in lieu of fees. Read SEC document |
| June 18, 2020 Filed Sep 24, 2020 00:28 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 8,929 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-20-018598 · dp137241_4-desouza.xml · nonDerivative · entry 1 DESOUZA ERROL B · CIK 0001213895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,644 Read SEC document |
| June 15, 2020 Filed Jun 18, 2020 01:49 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 35,715 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-20-011924 · dp130580_4-desouza.xml · nonDerivative · entry 1 DESOUZA ERROL B · CIK 0001213895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,715 Read SEC document |
| June 15, 2020 Filed Sep 24, 2020 00:28 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantLP interests in RPI US Partners 2019, LP · Derivative | 53,915 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950103-20-018598 · dp137241_4-desouza.xml · derivative · entry 2 DESOUZA ERROL B · CIK 0001213895 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Errol Bento De Souza Revocable Trust Disclosed balance after: 53,915 Underlying: Class A Ordinary Shares · 539,150 shares Expires not disclosed F1 · kind: The Reporting Person acquired beneficial ownership of Class B Interests in Royalty Pharma Holdings, Ltd. ("Holdings") and became entitled to indirect rights to exchange such Class B Interests for Class A Ordinary Shares of the Issuer in connection with a reorganization prior to closing of the Issuer's initial public offering (as more fully described in the Issuer's Registration Statement on Form S-1 (File No. 333-238632)). The reorganization involved the exchange of interests in Royalty Pharma Investments 2019 ICAV held by RPI US Partners 2019, LP ("RPI US LP") and RPI International Holdings 2019, LP ("RPI Intl. LP") for interests in Holdings. The reorganization and the acquisition of these exchange rights occurred on June 15, 2020. F2 · derivative.exercise_date: Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F2 · derivative.expiration_date: Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F3 · balance_after: Includes RPI US LP Interests convertible into 39,010 Class A Ordinary Shares that are subject to forfeiture if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The amount of this forfeiture scales linearly from 0% at $20.51 per share to 100% at $32.30 per share. Read SEC document |
| June 11, 2020 Filed Jun 12, 2020 20:44 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $7.18 | $0.00 |
DisclosureSEC source: 0001209191-20-036311 · doc4.xml · derivative · entry 1 DESOUZA ERROL B · CIK 0001213895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2030-06-11 F1 · derivative.exercise_date: The option shall vest monthly over a period of 12 months commencing June 11, 2020. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:37 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 2,860 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-023174 · doc4.xml · nonDerivative · entry 1 DESOUZA ERROL B · CIK 0001213895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,498 F1 · shares: Represents shares of common stock received in lieu of fees. Read SEC document |
| January 02, 2020 Filed Jan 2, 2020 21:44 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 1,835 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-000334 · doc4.xml · nonDerivative · entry 1 DESOUZA ERROL B · CIK 0001213895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,638 F1 · shares: Represents shares of stock received in lieu of fees. Read SEC document |
| October 01, 2019 Filed Oct 2, 2019 20:06 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 2,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-051609 · doc4.xml · nonDerivative · entry 1 DESOUZA ERROL B · CIK 0001213895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,803 F1 · shares: Represents shares of stock received in lieu of fees. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 20:33 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 1,810 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-040314 · doc4.xml · nonDerivative · entry 1 DESOUZA ERROL B · CIK 0001213895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,258 F1 · shares: Represents shares of stock received in lieu of fees. Read SEC document |
| June 13, 2019 Filed Jun 18, 2019 01:08 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $7.46 | $0.00 |
DisclosureSEC source: 0001209191-19-037567 · doc4.xml · derivative · entry 1 DESOUZA ERROL B · CIK 0001213895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2029-06-13 F1 · derivative.exercise_date: The option shall vest monthly over a period of 12 months commencing June 13, 2019. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 20:36 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 1,504 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-022525 · doc4.xml · nonDerivative · entry 1 DESOUZA ERROL B · CIK 0001213895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,448 F1 · shares: Represents shares of stock received in lieu of fees. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 22:43 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 1,703 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-001218 · doc4.xml · nonDerivative · entry 1 DESOUZA ERROL B · CIK 0001213895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,944 F1 · shares: Represents shares of stock received in lieu of fees. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 21:52 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $24.94 | $0.00 |
DisclosureSEC source: 0001209191-18-038134 · doc4.xml · derivative · entry 1 DESOUZA ERROL B · CIK 0001213895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2028-06-13 F1 · derivative.exercise_date: The option shall vest monthly over a period of 12 months commencing June 13, 2018. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 21:30 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | OtherRedeemable Convertible Note · Derivative | 4,679 | $0.00 Strike: $137.85 | $0.00 |
DisclosureSEC source: 0001209191-18-012430 · doc4.xml · derivative · entry 2 DESOUZA ERROL B · CIK 0001213895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33 shares Expires not disclosed F1 · derivative.exercise_price: Reflects a 1:15 reverse stock split effected on February 10, 2017. F2 · kind: Reflects a redeemable convertible note of the Issuer (the "Note") that matured, with the face value of the Note repaid to the Reporting Person. F3 · derivative.exercise_date: At the option of the Reporting Person, at any time on or before February 19, 2018, the Note was redeemable into cash at a rate of $1 for each $1 principal amount of the Note or convertible into shares of common stock of the Issuer at a conversion rate of $137.85 per share, respectively. F4 · derivative.expiration_date: The Note matured on February 19, 2018. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 21:30 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | OtherRedeemable Convertible Note · Derivative | Not disclosed | $0.00 Strike: $137.85 | $10,800.00 |
DisclosureSEC source: 0001209191-18-012430 · doc4.xml · derivative · entry 1 DESOUZA ERROL B · CIK 0001213895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 78 shares Expires not disclosed F1 · derivative.exercise_price: Reflects a 1:15 reverse stock split effected on February 10, 2017. F2 · kind: Reflects a redeemable convertible note of the Issuer (the "Note") that matured, with the face value of the Note repaid to the Reporting Person. F3 · derivative.exercise_date: At the option of the Reporting Person, at any time on or before February 19, 2018, the Note was redeemable into cash at a rate of $1 for each $1 principal amount of the Note or convertible into shares of common stock of the Issuer at a conversion rate of $137.85 per share, respectively. F4 · derivative.expiration_date: The Note matured on February 19, 2018. Read SEC document |
| July 13, 2017 Filed Jul 14, 2017 20:51 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $4.40 | $0.00 |
DisclosureSEC source: 0001209191-17-045212 · doc4.xml · derivative · entry 1 DESOUZA ERROL B · CIK 0001213895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-07-13 F1 · derivative.exercise_date: The option shall vest monthly over a period of 12 months commencing June 15, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.